Browse studies
Find your next paid study
16 recruiting studies matching your filters
Phase 1
Feasibility Study of CD34 Selection for GVHD Prophylaxis Using the Automated CliniMACS
Patients with graft failure or delayed engraftment may benefit from a hematopoietic stem cell boost or an additional hematopoietic stem cell transplantation pr…
AMLALLLymphoid Malignancies+3 more
Estimated
~$10 – $6,250
University of Alabama at BirminghamNCT06047886
Phase 1
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Partici…
MyelofibrosisPrimary MyelofibrosisPost-PV MF+1 more
Estimated
~$10 – $8,750
Telios Pharma, Inc.NCT05280509
Phase 3
A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include pa…
Thrombocythemia, EssentialPrimary MyelofibrosisMyelofibrosis+3 more
Estimated
~$10 – $8,750
Merck Sharp & Dohme LLCNCT06351631
Phase 2
A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)
This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philad…
Accelerated Phase Myeloproliferative NeoplasmBlast Phase Myeloproliferative NeoplasmEssential Thrombocythemia+5 more
Estimated
~$10 – $5,625
National Cancer Institute (NCI)NCT06661915